A phase 1/2 trial of XON7 in advanced solid tumours, run by Xenothera SAS, now recruiting.
FIH XON7 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06154291 by Xenothera SAS, with 255 participants planned, started 2023-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: XON7.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.